With the pathological variant where the two growth inhibitors p14ARF and p16INK4a are absent, this desired precedence might be compromised in favour of tumorigenesis, thus correlating with the observed CDKN2A gene deletion in bladder cancers [27,28]. The gene discussed is CDKN2A; the disease is urinary bladder carcinoma.